Patients’ Characteristics at Diagnosis and at Transplantation
| Patients studied | 181 (112 M; 69 F) |
| Mean age at diagnosis (yrs) | 8.1 ± 3.3 (range, 0.9-14.4) |
| Diagnosis and disease status at BMT | |
| 73 ALL (15-1st CR: 45-2nd CR: 11-≥2nd CR; 2 relapse) | |
| 46 AML 1st CR | |
| 10 CML chronic phase | |
| 2 Myelodisplastic syndrome | |
| 2 NHL | |
| 48 SAA | |
| Mean age at BMT (yrs) | 9.8 ± 2.6 (range, 1.5-14.9) |
| Type of BMT | |
| Allogeneic | 153 (149 identical sibling, 2 unrelated, 2 mismatched family donor) |
| Syngeneic | 3 |
| Autologous | 25 |
| GVHD | |
| Acute-grade 3-4 | 16 |
| Chronic-limited | 37 |
| Chronic-extended | 18 |
| Mean follow-up period (yrs) | 9.2 ± 3.1 (range, 2.9-19.7) |
| Patients studied | 181 (112 M; 69 F) |
| Mean age at diagnosis (yrs) | 8.1 ± 3.3 (range, 0.9-14.4) |
| Diagnosis and disease status at BMT | |
| 73 ALL (15-1st CR: 45-2nd CR: 11-≥2nd CR; 2 relapse) | |
| 46 AML 1st CR | |
| 10 CML chronic phase | |
| 2 Myelodisplastic syndrome | |
| 2 NHL | |
| 48 SAA | |
| Mean age at BMT (yrs) | 9.8 ± 2.6 (range, 1.5-14.9) |
| Type of BMT | |
| Allogeneic | 153 (149 identical sibling, 2 unrelated, 2 mismatched family donor) |
| Syngeneic | 3 |
| Autologous | 25 |
| GVHD | |
| Acute-grade 3-4 | 16 |
| Chronic-limited | 37 |
| Chronic-extended | 18 |
| Mean follow-up period (yrs) | 9.2 ± 3.1 (range, 2.9-19.7) |